| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2018 ( Subtotal = -$268,662 ) |
| | 2018 | 2017 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7TH ST STE 100 | BERKELEY | CA | 94710-2753 | ALAMEDA | USA | R44AI100376 | Developing small molecule inhibitors of TLR8 for treatment of rheumatoid arthritis | 002 | 4 | NIH | 6/19/2018 | -$343,664 |
| | 2018 | 2017 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7TH ST STE 100 | BERKELEY | CA | 94710-2753 | ALAMEDA | USA | R44AI100376 | Developing small molecule inhibitors of TLR8 for treatment of rheumatoid arthritis | 000 | 4 | NIH | 11/24/2017 | $16,295 |
| | 2018 | 2016 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7TH ST STE 100 | BERKELEY | CA | 94710-2753 | ALAMEDA | USA | R44AI100376 | Developing small molecule inhibitors of TLR8 for treatment of rheumatoid arthritis | 001 | 3 | NIH | 12/22/2017 | $58,707 |
|
| Issue Date FY: 2017 ( Subtotal = $406,490 ) |
| | 2017 | 2017 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7TH ST STE 100 | BERKELEY | CA | 94710-2753 | ALAMEDA | USA | R44AI100376 | Developing small molecule inhibitors of TLR8 for treatment of rheumatoid arthritis | 000 | 4 | NIH | 1/27/2017 | $406,490 |
|
| Issue Date FY: 2016 ( Subtotal = $530,775 ) |
| | 2016 | 2016 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | R44AI100376 | Developing small molecule inhibitors of TLR8 for treatment of rheumatoid arthritis | 001 | 3 | NIH | 2/15/2016 | -$530,775 |
| | 2016 | 2016 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | R44AI100376 | Developing small molecule inhibitors of TLR8 for treatment of rheumatoid arthritis | 001 | 3 | NIH | 2/15/2016 | $530,775 |
| | 2016 | 2016 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R44AI100376 | Developing small molecule inhibitors of TLR8 for treatment of rheumatoid arthritis | 000 | 3 | NIH | 2/11/2016 | $530,775 |
|
| Issue Date FY: 2015 ( Subtotal = $198,117 ) |
| | 2015 | 2015 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R21OD018317 | Generation of a Transgenic Mouse Model to Study Human TLR9 Role in Disease | 000 | 2 | NIH | 4/29/2015 | $198,117 |
|
| Issue Date FY: 2014 ( Subtotal = $227,161 ) |
| | 2014 | 2014 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R21OD018317 | Generation of a Transgenic Mouse Model to Study Human TLR9 Role in Disease | 000 | 1 | NIH | 8/1/2014 | $227,161 |
|
| Issue Date FY: 2013 ( Subtotal = $627,986 ) |
| | 2013 | 2013 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R43AI096641 | DEVELOPMENT OF TLR8 INHIBITORS FOR TREATMENT OF AUTOIMMUNE DISEASES | 000 | 2 | NIH | 5/23/2013 | $299,508 |
| | 2013 | 2013 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R41DK101221 | THE DEVELOPMENT OF TLR ANTAGONISTS FOR THERAPY OF HEPATIC FIBROSIS AND CIRRHOSIS | 000 | 1 | NIH | 9/20/2013 | $223,390 |
| | 2013 | 2013 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R43AI100376 | SCREENING FOR INHIBITORS OF TLR8 FOR TREATMENT OF RHEUMATOID ARTHRITIS | 000 | 2 | NIH | 6/7/2013 | $105,088 |
|
| Issue Date FY: 2012 ( Subtotal = $891,697 ) |
| | 2012 | 2012 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R43AI092929 | INHIBITORS OF PI3K-DELTA FOR TREATMENT OF SKIN INFLAMMATION | 000 | 2 | NIH | 6/22/2012 | $292,359 |
| | 2012 | 2012 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R43AI100376 | SCREENING FOR INHIBITORS OF TLR8 FOR TREATMENT OF RHEUMATOID ARTHRITIS | 000 | 1 | NIH | 5/29/2012 | $299,830 |
| | 2012 | 2012 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R43AI096641 | DEVELOPMENT OF TLR8 INHIBITORS FOR TREATMENT OF AUTOIMMUNE DISEASES | 001 | 1 | NIH | 6/4/2012 | $70,775 |
| | 2012 | 2012 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R43AI096641 | DEVELOPMENT OF TLR8 INHIBITORS FOR TREATMENT OF AUTOIMMUNE DISEASES | 000 | 1 | NIH | 5/22/2012 | $228,733 |
|
| Issue Date FY: 2011 ( Subtotal = $594,425 ) |
| | 2011 | 2011 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R43AI092929 | INHIBITORS OF PI3K-DELTA FOR TREATMENT OF SKIN INFLAMMATION | 000 | 1 | NIH | 7/18/2011 | $297,225 |
| | 2011 | 2011 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R43CA154078 | DEVELOPMENT OF AN L2-BASED HPV VACCINE TO GENERATE BROAD IMMUNITY | 000 | 2 | NIH | 7/14/2011 | $297,200 |
|
| Issue Date FY: 2010 ( Subtotal = $659,534 ) |
| | 2010 | 2010 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R43CA154078 | DEVELOPMENT OF AN L2-BASED HPV VACCINE TO GENERATE BROAD IMMUNITY | 000 | 1 | NIH | 7/7/2010 | $298,625 |
| | 2010 | 2010 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R43AI082839 | INHIBITORS OF TOLL-LIKE RECEPTORS 7 & 9 FOR TREATMENT OF SKIN INFLAMMATION | 000 | 2 | NIH | 3/18/2010 | $360,909 |
|
| Issue Date FY: 2009 ( Subtotal = $1,291,940 ) |
| | 2009 | 2009 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R44AI066483 | DEVELOPMENT OF AN INHIBITORY OLIGONUCLEOTIDE FOR THE TREATMENT OF LUPUS | 000 | 3 | NIH | 6/25/2009 | $932,510 |
| | 2009 | 2009 | DYNAVAX TECHNOLOGIES CORPORATION | 2929 7th St Ste 100 | Berkeley | CA | 94710-2753 | ALAMEDA | USA | R43AI082839 | INHIBITORS OF TOLL-LIKE RECEPTORS 7 & 9 FOR TREATMENT OF SKIN INFLAMMATION | 000 | 1 | NIH | 3/27/2009 | $359,430 |
|
| Issue Date FY: 2008 ( Subtotal = $2,495,206 ) |
| | 2008 | 2008 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | R44AI066483 | DEVELOPMENT OF AN INHIBITORY OLIGONUCLEOTIDE FOR THE TREATMENT OF LUPUS | 000 | 2 | NIH | 7/7/2008 | $878,519 |
| | 2008 | 2008 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | U01AI074578 | PRODUCTION OF AN NP-ISS CONJUGATE VACCINE TO COMBAT PANDEMIC INFLUENZA. | 000 | 2 | NIH | 8/6/2008 | $1,616,687 |
|
| Issue Date FY: 2007 ( Subtotal = $1,600,000 ) |
| | 2007 | 2007 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | U01AI074578 | PRODUCTION OF AN NP-ISS CONJUGATE VACCINE TO COMBAT PANDEMIC INFLUENZA. | 000 | 1 | NIH | 8/6/2007 | $1,600,000 |
|
| Issue Date FY: 2006 ( Subtotal = $4,073,182 ) |
| | 2006 | 2006 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | U01AI056559 | ADVANCED ANTHRAX VACCINE MADE WITH ISS DNA FORMULATIONS | 000 | 4 | NIH | 1/25/2006 | $2,098,735 |
| | 2006 | 2006 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | R43AI066483 | DEVELOPMENT OF AN INHIBITORY OLIGONUCLEOTIDE FOR THE TREATMENT OF LUPUS | 000 | 1 | NIH | 7/20/2006 | $207,278 |
| | 2006 | 2006 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | U01AI056447 | ISS-LINKED NP VACCINE TO CONTROL PANDEMIC FLU OUTBREAK | 000 | 4 | NIH | 7/17/2006 | $1,767,169 |
|
| Issue Date FY: 2004 ( Subtotal = $1,597,904 ) |
| | 2004 | 2004 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | U01AI056435 | IMMUNOSTIMULATORY DNA PRIMING OF LUNG INNATE IMMUNITY | 000 | 2 | NIH | 5/24/2004 | $759,577 |
| | 2004 | 2004 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | U01AI056559 | ADVANCED ANTHRAX VACCINE MADE WITH ISS DNA FORMULATIONS | 000 | 2 | NIH | 1/23/2004 | $456,128 |
| | 2004 | 2004 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | U01AI056447 | ISS-LINKED NP VACCINE TO CONTROL PANDEMIC FLU OUTBREAK | 000 | 2 | NIH | 2/10/2004 | $382,199 |
|
| Issue Date FY: 2003 ( Subtotal = $1,280,206 ) |
| | 2003 | 2003 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | U01AI056559 | ADVANCED ANTHRAX VACCINE MADE WITH ISS DNA FORMULATIONS | 000 | 1 | NIH | 7/11/2003 | $234,644 |
| | 2003 | 2003 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | U01AI056447 | ISS-LINKED NP VACCINE TO CONTROL PANDEMIC FLU OUTBREAK | 000 | 1 | NIH | 8/8/2003 | $305,747 |
| | 2003 | 2003 | DYNAVAX TECHNOLOGIES CORPORATION | 717 POTTER STREET SUITE 100 | BERKELEY | CA | 94710 | ALAMEDA | USA | U01AI056435 | IMMUNOSTIMULATORY DNA PRIMING OF LUNG INNATE IMMUNITY | 000 | 1 | NIH | 9/29/2003 | $739,815 |
|
| Issue Date FY: 2002 ( Subtotal = $119,349 ) (Continued on the next page) |
|
